About Onco'Zine

Onco’Zine - The International Cancer Network- publishes a broad range of topics and timely news updates with information from all oncology disciplines and subspecialties. Onco'Zine is a sponsor-supported, interactive online community for healthcare professionals involved in the management and care of cancer patients.

© 2004 - 2013 Onco'Zine (ISSN 2168-5339) is published by InPress Media Group, LLC.
605 E. Grant Street, Suite 106,
Phoenix, AZ 85004
Editorial Office:
4960 S. Gilbert Rd, Suite 1-286,
Chandler, AZ 85249

Advertisement

CA: A Cancer Journal for Clinicians

Loading… Loading feed

ADVERTISEMENT

Oncology Headline News

Loading… Loading feed

Cancer Biotherapy & Radiopharmaceuticals - Table of Contents

Loading… Loading feed

Cure Today (Blog)

Loading… Loading feed

 

Blog Posts

Fewer Infections and Less Clotting Associated with Neutral Fluid Displacement Connector

Posted by Editorial Team on May 21, 2013 at 4:00pm 0 Comments

The design of intravenous needleless connectors or NCs plays a substantial role in development of the potentially deadly hospital acquired-catheter related blood stream infection (HA-CRBSI) and the associated risk. Research on different types…

Continue

Erlotinib is the First Personalized Medicine Approved for the Initial Treatment of People with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer

Posted by Editorial Team on May 14, 2013 at 8:30pm 0 Comments

The U.S. Food and Drug Administration (FDA) has approved erlotinib tablets (Tarceva®; Genentech, Astellas Pharma), a once-daily, oral…

Continue

Angelina Jolie: A Difficult Choice and A Courageous Decision

Posted by Editorial Team on May 14, 2013 at 9:30am 1 Comment

In an op-ed article titled "My Medical Choice" published earlier today in the New York Times, famed Hollywood actress…

Continue

Enzastaurin Does Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma Study

Posted by Peter Hofland, PhD on May 10, 2013 at 6:00am 0 Comments

Phase III clinical trial results from PRELUDE study, which explored the enzastaurin (Eli Lilly and Company;…

Continue

Study Evaluates Treatment of High Dose Aldesleukin + Vemurafenib in Patients with Metastatic Melanoma

Posted by Peter Hofland, PhD on May 9, 2013 at 10:00am 0 Comments

A new multi-center trial of high dose Interleukin-2 (HD rIL-2; Aldesleukin for Injection/Proleukin®; Prometheus Laboratories…

Continue

New Diagnostic Test Effectively Predicts Rapid Metastatic Prostate Cancer (RMD) - Outperforms Existing Tools

Posted by Editorial Team on May 8, 2013 at 9:00pm 0 Comments

Data presented today at the 2013 Annual Meeting for the American Urological Association by Johns Hopkins University School of Medicine researchers demonstrated that Decipher™ (…

Continue

UK Charity Calls for More Attention and Awareness for Bladder Cancer

Posted by Peter Hofland, PhD on May 7, 2013 at 9:30pm 0 Comments

Data from various cancer registries in the United Kingdom shows that Bladder Cancer is a common cancer among men and women in the United Kingdom, with 10.335 new cases diagnosed in 2008. [1][2][3][4] It is one of the most frequently diagnosed…

Continue

Cryoablation Shows Promising Results in the Treatment of Breast Cancer

Posted by Peter Hofland, PhD on May 7, 2013 at 5:30pm 0 Comments

Date presented at the 2013 Conference of The American Society of Breast Surgeons (ASBrS) shows promising results for non-surgical cryoablation treatment of breast cancer. The results were presented by Eisuke Fukuma, M.D., Ph.D., Chairman and…

Continue

Phase III Head-to-Head Study of Panitumumab Against Cetuximab in Metastatic Colorectal Cancer Meets Primary Endpoint of Non-Inferiority in Monotherapy Setting

Posted by Peter Hofland, PhD on May 7, 2013 at 3:00pm 0 Comments

Results of the ASPECCT ('763) trial, a phase III head-to-head study evaluating panitumumab (Vectibix®; Amgen Inc.) versus cetuximab (…

Continue

Physical Activity may help Reduce Breast Cancer Risk by Altering Estrogen Metabolism

Posted by Editorial Team on May 7, 2013 at 1:00pm 0 Comments

Changes in estrogen breakdown, or metabolism, may be one of the mechanisms by which aerobic exercise lowers a woman’s breast cancer risk. A study discussing data that suggests that exercise influences estrogen metabolism was published earlier…

Continue

Videos

  • Add Videos
  • View All

Photos

Loading…
  • Add Photos
  • View All

ADVERTISEMENT

Medscape Hematology-Oncology Headlines

Loading… Loading feed

The Lancet Oncology

Loading… Loading feed

European Journal of Cancer

Loading… Loading feed

American Journal of Cancer - Most Popular Articles

Loading… Loading feed

American Journal of Clinical Oncology - Current Issue

Loading… Loading feed

Journal of Clinical Oncology - Last 3 Issue (ASCO)

Loading… Loading feed

Media Partner

Media Partner

Oncology

Loading… Loading feed

Case Reports in Oncology

Loading… Loading feed

Cancer Epidemiology

Loading… Loading feed

Journal of Geriatric Oncology Current

First immunochemotherapy outcomes in elderly patients with CLL: A retrospective analysis

Abstract: Background: To date, the majority of trials on chronic lymphocytic leukemia (CLL) focused on patients considerably younger than the median age of onset for CLL. As a result, no definitive treatment exists for elderly patients, especially less medically fit patients.Objectives: The objectives of this study are to examine the impact of comorbidities on outcome as well as to compare three different therapeutic regimens in outcome efficacy.Materials and Methods: We retrospectively identified 143 patients aged >65 years, who received fludarabine, cyclophosphamide, and rituximab (FCR) (n=49), fludarabine and rituximab (FR) (n=74), or rituximab with chlorambucil (R–CLB) (n=20) as first initial immunochemotherapy.Results: At current follow-up (median: 24 months), the proportion of patients with a clinical response was higher with FCR (75%) than FR (57%) and R–CLB (28%). For FCR, FR, and R–CLB patients, 2-year overall survival (OS) was 94%, 76%, and 73%, respectively, (p=0.14), while 2-year progression-free survival (PFS) was 90%, 58%, and 30% (p<0.001). In the fludarabine based regimen (FR and FCR) population, higher rituximab doses (500mg/m2 vs. 375mg/m2) correlated with prolonged PFS.Conclusion: Despite the retrospective nature of this study, we demonstrate that elderly patients with CLL benefit from frontline immunochemotherapy, and emphasize the importance of maintaining rituximab dose intensity.

Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy

Abstract: Objectives: Elderly patients with diffuse large B cell lymphoma (DLBCL) without prohibitive co-morbidities may be cured with standard immuno-chemotherapeutic regimens, as used in younger patients. Less is known about the survival prospects in older people, if first-line therapy fails. This study aimed to provide additional information regarding prognosis in this group.Materials and Methods: Databases were collated from three randomized trials of first-line therapy in those aged 60 and over, deemed fit enough for standard therapy. Overall survival from the point of treatment failure was calculated and comparisons were made between age groups and types of treatment failure.Results: Overall survival (OS) at 2years in 862 patients was 46%, 38%, 37% and 23%, respectively, for those aged 60–64, 65–69, 70–74 and >74. Type of treatment failure impacted on 2year OS as follows: initial partial remission (PR): 48%; complete response (CR) with late relapse: 37%; CR with early relapse: 17%; and less than PR to initial therapy: 12%.Conclusion: Older patients failing first-line therapy for DLBCL should be counseled differently regarding prognosis depending upon age and type of treatment failure. The chance of survival was greater in those achieving PR or CR with relapse more than 12months from diagnosis. This data may support the consideration of aggressive salvage therapy in fit patients in these categories, regardless of biological age per se. Palliative management may be more appropriate for those achieving less than PR to initial therapy or who enter CR but relapse within one year of diagnosis.

Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer

Abstract: Objective: The combination of oxaliplatin and oral capecitabine (XELOX) has shown to be an active regimen in metastatic colorectal cancer (MCRC). However, the experience with XELOX in elderly patients is limited. This study aimed to evaluate the efficacy and safety of XELOX as first-line treatment in elderly patients with MCRC.Patients and Methods: Patients aged ≥70years with previously untreated MCRC received oxaliplatin 85mg/m2 on day 1, every 2weeks plus capecitabine 1000mg/m2 (or capecitabine 750mg/m2 if creatinine clearance was 30–50mL/min) twice daily on days 1–7, every 2weeks. Treatment was continued until progression, intolerable toxicity, or for a maximum of 12cycles.Results: Thirty-five patients were enrolled. Median age was 78years (range, 70–83). Patients received a median of 11cycles of treatment. The objective response rate (ORR) was 49% and the tumor control rate was 86%. Median time to progression and overall survival were 8.6 (95% CI: 5.5–11.7) and 15.5 (95% CI: 9.6–21.3) months, respectively. Toxicities were generally mild to moderate. Major grade 1–2 toxicities were asthenia (40%), nausea (43%), and diarrhea (40%). No grade 4 toxicity was detected and grade 3 toxicities were reported in 17% of patients. There was no treatment-related death.Conclusion: Our findings show that the biweekly XELOX regimen represents an effective and tolerable first-line treatment option for elderly patients with MCRC.

Oncology Tube

Loading… Loading feed

 
 
 

ADVERTISEMENT

Onco'Zine is present here

The Lancet Oncology (Podcast)

Loading… Loading feed

Meet us on Facebook

Hematology Headlines

Loading… Loading feed

Breast Cancer Headlines

Loading… Loading feed

Colorectal Cancer Headlines

Loading… Loading feed

Melanoma Headlines

Loading… Loading feed

Ovarian Cancer Headlines

Loading… Loading feed

Prostate Cancer Headlines

Loading… Loading feed

© 2013   Created by Peter Hofland, PhD.

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+